Barbara Denysiak, MD
General Practice · San Diego, CANPI 1003085572
Payments from drug & device makers
Across 535 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- AstraZeneca$2K
- Johnson & Johnson$2K
- Biohaven Pharmaceutical Holding Company Ltd.$2K
- Gilead$2K
- GSK$1K
- plus $4K from 25 others
What the payments were for
- Consulting fees$1,2007%
- Travel & lodging$3612%
- Food & beverage$16,06591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 177 | $3,951 |
| AstraZeneca | 63 | $2,418 |
| Johnson & Johnson | 75 | $2,383 |
| Biohaven Pharmaceutical Holding Company Ltd. | 14 | $2,366 |
| Gilead | 60 | $1,593 |
| GSK | 17 | $1,274 |
| Novo Nordisk | 24 | $757 |
| Vanda Pharmaceuticals Inc. | 30 | $710 |
| Bayer | 20 | $591 |
| Lilly USA, LLC | 10 | $332 |
| Viiv Healthcare Company | 8 | $233 |
| Si-bone, Inc. | 3 | $220 |
| Sanofi-aventis U.S. LLC | 2 | $145 |
| Pfizer | 7 | $111 |
| Boehringer Ingelheim | 3 | $73 |
| Biohaven Pharmaceuticals, Inc. | 3 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| IBSA Pharma Inc. | 2 | $35 |
| Astellas Pharma US Inc | 1 | $34 |
| Terumo BCT, Inc. | 1 | $30 |
| Radius Health, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Amgen | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Mannkind Corporation | 1 | $19 |
| Abbott | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Spinal Simplicity, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,626 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 76 | $80,720 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 96 | $73,518 |
| FarxigaDapagliflozin Propanediol | 47 | $53,756 |
| JardianceEmpagliflozin | 34 | $47,612 |
| EliquisApixaban | 26 | $41,065 |
| RybelsusSemaglutide | 19 | $28,184 |
| XareltoRivaroxaban | 19 | $21,883 |
| TrulicityDulaglutide | 23 | $21,420 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $12,420 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,294 |
| Levothyroxine Sodium | 330 | $4,043 |
| Celecoxib | 71 | $3,972 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $3,790 |
| Gabapentin | 143 | $3,684 |
| Atorvastatin Calcium | 344 | $3,298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $757 | $108,90595 claims |
| GSKTrelegy Ellipta | $1,274 | $73,51896 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,418 | $61,05159 claims |
| Boehringer IngelheimJardiance | $73 | $47,61234 claims |
| PfizerEliquis | $111 | $41,06526 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $332 | $22,25343 claims |
| Johnson & JohnsonXarelto | $2,383 | $21,88319 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $145 | $12,42014 claims |
| AbbVieSynthroid | $3,951 | $1,27320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.
Other general practice in San Diego
- Marc RubinsteinSan Diego$232K
- Shivi GuptaSan Diego$131K
- Hessam AazamiCanoga Park$88.4M
- Frederic MollRedwood City$5.7M
- Nathan LiLancaster$5.2M
- Milton McCollSan Jose$4.9M
- Bruce TorkanLos Angeles$3.8M
- Daniel JohnsonPalm Desert$1.5M
- Bradley ChingUpland$1.4M
- Jared AdamsSan Francisco$862K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.